Tarsus Pharmaceuticals
TARS
TARS
116 hedge funds and large institutions have $692M invested in Tarsus Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 48 increasing their positions, 22 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
116
Holders Change
+11
Holders Change %
+10.48%
% of All Funds
1.7%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
28
Increased
48
Reduced
22
Closed
17
Calls
$2.99M
Puts
$458K
Net Calls
+$2.53M
Net Calls Change
+$2.26M
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$77.8M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
+$20.8M |
| 3 |
BlackRock
New York
|
+$6.19M |
| 4 |
RI
RTW Investments
New York
|
+$5.5M |
| 5 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$4.86M |
Top Sellers
| 1 |
DM
Deerfield Management
New York
|
-$13.4M |
| 2 |
Millennium Management
New York
|
-$12.3M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
-$9.68M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$8.1M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$4.44M |
